Fluconazole Prophylaxis in High-Risk Neonates

Author:

Reed Brent N1,Caudle Kelly E2,Rogers P David3

Affiliation:

1. Brent N Reed PharmD, Pharmacy Practice Resident, University of North Carolina Hospitals & Clinics, Chapel Hill, NC

2. Kelly E Caudle PharmD, PhD candidate in Pharmaceutical Sciences, Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, TN; LeBonheur Children's Medical Center, Memphis

3. P David Rogers PharmD PhD FCCP, First Tennessee Chair of Excellence in Pediatric Clinical Pharmacy; Associate Dean for Translational Research; Professor and Vice Chair, Department of Clinical Pharmacy, Le Bonheur Children's Medical Center

Abstract

OBJECTIVE To evaluate the literature regarding the use of fluconazole prophylaxis in high-risk neonates. DATA SOURCES Literature was accessed through MEDLINE (February 2001-August 2009) using the search terms fluconazole and prophylaxis, with limits for age group (ie, birth-18 y). Reference citations from identified articles were also reviewed. DATA SELECTION AND DATA EXTRACTION All prospective and retrospective studies in English identified from MEDLINE were evaluated. DATA SYNTHESIS Critically ill neonates possess a number of risk factors that predispose them to fungal colonization with Candida spp. In many cases, colonization may progress to invasive systemic infections despite efforts aimed at early diagnosis and treatment. Because of its success among immunocompromised patients, fluconazole prophylaxis has been suggested as a possible approach for reducing the rates of both colonization and invasive fungal infections among at-risk neonates. To date, 4 prospective randomized controlled trials and 8 retrospective cohort studies have examined fluconazole prophylaxis in neonates. Although fluconazole prophylaxis appears to reduce the rates of colonization and invasive fungal infections, no trial in this review was able to demonstrate a significant difference in long-term morbidity or mortality. Concerns also remain regarding the adverse effects associated with prolonged exposure to fluconazole therapy. Lack of standardized study designs and treatment regimens also limit widespread recommendation for the use of fluconazole prophylaxis in clinical practice. CONCLUSIONS While it may be beneficial for critically ill neonates with certain predisposing risk factors (eg, central venous access, sustained exposure to broad-spectrum antibiotics, or units with significantly high incidence of invasive fungal infections), existing research does not support the use of fluconazole prophylaxis based on birth weight or gestational age alone. Multifactor analysis evaluating the effect of fluconazole prophylaxis is necessary to establish which neonates would benefit from this practice.

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Dermatología neonatal;EMC - Dermatología;2018-03

2. Neonatal Vascular Access;Rickham's Neonatal Surgery;2018

3. Fluconazole Doses Used for Prophylaxis of Invasive Fungal Infection in Neonatal Intensive Care Units: A Network Meta-Analysis;The Journal of Pediatrics;2017-06

4. Efficacy of Fluconazole Prophylaxis for Invasive Fungal Infection in Extremely Low Birth Weight Infants;Journal of Korean Society of Health-System Pharmacists;2014-08

5. Fungal Prophylaxis in Neonates;Advances in Neonatal Care;2014-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3